Fc variants with altered binding to FcRn
US-9200079-B2 · Dec 1, 2015 · US
Fc variants with altered binding to FcRn
US9803023B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9803023-B2 |
| Application number | US-201514930383-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 2, 2015 |
| Priority date | Nov 12, 2004 |
| Publication date | Oct 31, 2017 |
| Grant date | Oct 31, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
First claim
Opening claim text (preview).
We claim: 1. A polypeptide comprising an Fc variant of a human IgG Fc polypeptide, wherein said Fc variant comprises a serine at position 434, and wherein numbering is according to the EU index in Kabat et al. 2. A polypeptide comprising an Fc variant according to claim 1 , wherein said polypeptide is an antibody. 3. A polypeptide according to claim 2 , wherein said polypeptide comprising an Fc variant has specificity for a target molecule that is selected from the group consisting of a cytokine, a soluble protein factor, and a protein expressed on cancer cells. 4. An antibody according to claim 2 , wherein said antibody is selected from the group consisting of a chimeric antibody, a humanized antibody, or a human antibody. 5. A polypeptide comprising an Fc variant according to claim 1 , wherein said polypeptide is an Fc fusion. 6. A method of producing a polypeptide comprising an Fc variant according to claim 1 , said method comprising providing a cell comprising a nucleic acid encoding said polypeptide, wherein said cell is cultured under conditions suitable for expression of said polypeptide. 7. A method according to claim 6 , wherein said nucleic acid is contained in an expression vector. 8. A host cell comprising a nucleic acid encoding a polypeptide comprising an Fc variant according to claim 1 . 9. An expression vector, wherein said expression vector encodes a polypeptide comprising an Fc variant according to claim 1 .
Assignees
Inventors
Classifications
Constant or Fc region; Isotype · CPC title
- C07K16/32Primary
against translation products of oncogenes · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Decreased effector function due to an Fc-modification · CPC title
against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9803023B2 cover?
- The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
- Who is the assignee on this patent?
- Xencor Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/32. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).